Merck + Co., Inc.

Janssen Pharmaceutica Nv

Michael P Neeper

Kathrin Ute Jansen

Joseph G Joyce

Loren D Schultz

Kathryn J Hofmann

Hugh A George

William L McClements

Lloyd H Waxman

Christopher M Flores

Victor M Garsky

Ning Qin

Henry Z Markus

Ling Chen

Robert S Lowe

Xin-Min Wang

E Dale Lehman

George P Vlasuk

Thomas M Connolly

James C Cook, Iii

Yi Liu

Tasha Hutchinson

Jessica Ching-Yee Ling

Kathryn J Hofman

A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel.

Canine transient receptor potential V2 (cTRPV2) and methods of screening for TRPV2 channel modulators

It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2.

Compositions and methods for identifying modulators of TRPV2

Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.

Optimized expression of HPV 31 L1 in yeast

Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity 

Optimized expression of HPV31 L1 in yeast

Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.

Synthetic human papilloma virus genes

Synthetic human papillomavirus genes

Human Papillomavirus virus like particles (VLPs) have been constructed so that they contain a modified L2 protein. The L2 protein has been minimized and is fused to a second protein or peptide. The fused protein is incorporated into the VLP and the VLP can deliver the protein to a cell. The modified VLPs can be used to increase the breadth of immune response in vaccine preparations or to deliver other proteins of interest.

Protein delivery system using human papillomavirus virus-like particles

The present invention is directed to DNA molecules encoding purified human papillomavirus type 18 and derivatives thereof.

DNA encoding human papilloma virus type 18

Synthetic HPV6/11 hybrid L1 DNA encoding human papillomavirus type 11 L1

DNA encoding human papillomavirus type 18

The present invention is directed to a recombinant human papillomavirus type 11 L1 protein encoded by a synthetic DNA molecule and methods of making and using the protein.

Production of recombinant human papillomavirus type II protein utilizing

The present invention is directed to vaccines for human papillomavirus type 18 and derivatives thereof.

Recombinant human papillomavirus type 18 vaccine

Proteins which specifically inhibit coagulation Factor Xa. The inhibitors, which do not inhibit Factor VIIa, kallikrein, trypsin, chymotrypsin, thrombin, urokinase, tissue plasminogen activator, plasmin, elastase, Factor XIa or S. aureus V8 protease, are polypeptides of 60 amino acid residues. The inhibitors may be purified from Ornithodoros moubata extract, synthesized, or produced using a recombinant DNA yeast expression system.

Processes for making proteins having anticoagulant properties

The invention comprises proteinaceous substances isolated from crude Ornithodoros moubata extract which inhibit adhesion of platelets to collagen. These substances do not inhibit platelet adhesion to fibrinogen, and are therefore particularly useful for inhibiting adhesion of platelets to collagen when simultaneous inhibition of platelet adhesion to fibrinogen is undesired. They are particularly useful in the prevention, prophylaxis, therapy and treatment of thrombotic diseases.

Growing community of inventors

Collegeville, PA, United States of America

Michael P Neeper